About: Iratumumab

Property	Value
dbo:abstract	إيراتوموماب هو جسم مضاد وحيد النسيلة بشري يستخدم في علاج لمفومة هودجكين، طورته . (ar) Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease. This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb. The FDA granted orphan drug designation for Hodgkin's lymphoma in 2004. In 2009, development was suspended with no explanation given. (en) Il Iratumumab è un anticorpo monoclonale di tipo umano, che viene utilizzato per il trattamento di malattie oncologiche come il linfoma recidivante con recettori del TNF positivi. Il farmaco agisce sull'antigene: CD30. Esso è stato sviluppato dalla Inc.. (it)
dbo:casNumber	640735-09-7
dbo:fdaUniiCode	AYH22O1B1U
dbo:kegg	D04612
dbo:wikiPageID	9700495 (xsd:integer)
dbo:wikiPageLength	2008 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1000891252 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Human dbr:CD30 dbr:Medarex dbr:Monoclonal_antibody dbc:Experimental_cancer_drugs dbr:Bristol-Myers_Squibb dbc:Monoclonal_antibodies_for_tumors dbr:Hodgkin's_disease dbr:Orphan_drug_designation
dbp:atcPrefix	none (en)
dbp:c	6358 (xsd:integer)
dbp:casNumber	640735 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	9830 (xsd:integer)
dbp:kegg	D04612 (en)
dbp:mabType	mab (en)
dbp:n	1682 (xsd:integer)
dbp:o	1992 (xsd:integer)
dbp:s	38 (xsd:integer)
dbp:source	u (en)
dbp:target	dbr:CD30
dbp:type	mab (en)
dbp:unii	AYH22O1B1U (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	458270691 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Refimprove dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Monoclonal-antibody-stub dbt:Monoclonals_for_tumors
dcterms:subject	dbc:Experimental_cancer_drugs dbc:Monoclonal_antibodies_for_tumors
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:WikicatMonoclonalAntibodiesForTumors yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 umbel-rc:DrugProduct
rdfs:comment	إيراتوموماب هو جسم مضاد وحيد النسيلة بشري يستخدم في علاج لمفومة هودجكين، طورته . (ar) Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease. This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb. The FDA granted orphan drug designation for Hodgkin's lymphoma in 2004. In 2009, development was suspended with no explanation given. (en) Il Iratumumab è un anticorpo monoclonale di tipo umano, che viene utilizzato per il trattamento di malattie oncologiche come il linfoma recidivante con recettori del TNF positivi. Il farmaco agisce sull'antigene: CD30. Esso è stato sviluppato dalla Inc.. (it)
rdfs:label	إيراتوموماب (ar) Iratumumab (it) Iratumumab (en)
owl:sameAs	freebase:Iratumumab yago-res:Iratumumab wikidata:Iratumumab dbpedia-ar:Iratumumab dbpedia-it:Iratumumab https://global.dbpedia.org/id/3Wd1b dbr:Iratumumab
prov:wasDerivedFrom	wikipedia-en:Iratumumab?oldid=1000891252&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Iratumumab
is dbo:wikiPageWikiLink of	dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Iq–Iv
is foaf:primaryTopic of	wikipedia-en:Iratumumab